Development and evaluation of an automated approach to the measurement and design of icons

by Forsythe, A. M.
Published 2004

What Does the Economic Burden of Acute Myeloid Leukemia Treatment Look Like for the Next Decade? An Analysis of Key Findings, Challenges and Recommendations

by Forsythe A, Sandman KE
Published 2021-05-01

The humanistic and economic burden associated with increasing body mass index in the EU5

by Gupta S, Richard L, Forsythe A
Published 2015-07-01

Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review

by Forsythe A, Kwon CS, Bell T, Smith TA, Arondekar B
Published 2019-01-01

Systematic review of health state utility values for acute myeloid leukemia

by Forsythe A, Brandt PS, Dolph M, Patel S, Rabe APJ, Tremblay G
Published 2018-01-01

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

by Tremblay G, Chandiwana D, Dolph M, Hearnden J, Forsythe A, Monaco M
Published 2018-05-01

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer

by Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G
Published 2018-05-01

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

by Gianoukakis AG, Flores NM, Pelletier CL, Forsythe A, Wolfe GR, Taylor MH
Published 2016-05-01

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States

by Tremblay G, Said Q, Roy AN, Cai B, Ashton Garib S, Hearnden J, Forsythe A
Published 2019-11-01

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

by Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G
Published 2018-05-01

Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer

by Fordham BA, Kerr C, de Freitas HM, Lloyd AJ, Johnston K, Pelletier CL, Tremblay G, Forsythe A, McIver B, Cohen EEW
Published 2015-11-01